What does resectability mean in NSCLC?

Dr. M. Brandao explains the consensual definition of stage III NSCLC by the EORTC working group

Neoadjuvant immunochemotherapy, the pneumo-oncologist’s perspective

Prof. N. Girard presents a patient with a PD-L1+ primary lung adenocarcinoma, with a resectable tumor. There’s a discussion on the treatment decision, prediction of pathological complete response and potential need for adjuvant immunotherapy after neoadjuvant chemoimmunotherapy.

Neoadjuvant immunochemotherapy, the thoracic surgeon’s perspective

Prof. J. Spicer guides the audience through a discussion about 3 different patient cases. Each of them presents a particular challenge: 1) One patient, many stages. 2) Bilateral synchronous lung cancer and biomarker informed therapy. 3) Unresectable or borderline resectable?